AbbVie Completes Acquisition of Capstan Therapeutics

Core Insights - AbbVie has completed the acquisition of Capstan Therapeutics, enhancing its capabilities in developing innovative therapies for B cell-mediated autoimmune diseases [1][3] Company Overview - AbbVie aims to discover and deliver innovative medicines addressing serious health issues across key therapeutic areas including immunology, oncology, neuroscience, and eye care [4] Acquisition Details - Capstan's lead asset, CPTX2309, is currently in Phase 1 trials and utilizes a targeted lipid nanoparticle (tLNP) platform to generate CD19-specific, CD8+ in vivo CAR-T cells, which are designed for rapid and deep B cell depletion [2][3] - The acquisition strengthens AbbVie's ability to deliver new treatments that can reset the immune system and allows broader application of Capstan's proprietary technology for in vivo cell programming [3]